|
Hyderabad, Sep 23: Bharat Biotech on Wednesday signed a licensing agreement with Washington University School of Medicine in St Louis, US for a novel “chimp-adenovirus”, single dose intranasal vaccine for COVID-19.
According to a press release issued by the city-based vaccine maker, Bharat Biotech owns the rights to distribute the vaccine in all markets except the US, Japan and Europe.
Representational Image
While the Phase I trial will take place in St Louis University’s Vaccine and Treatment Evaluation Unit, Bharat Biotech, upon obtaining the required regulatory approval, will pursue further…
